Biomarker ID | 291 |
PMID | 18553995 |
Year | 2008 |
Biomarker | Chondroitin sulfate proteoglycan 2 (Versican) variant (Fragment) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated (Mean Ratio: 2.28 ±0.58) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-Tetrasaccharide linker sequence formation in glycosaminoglycan biosynthesis,Endogenous Toll-like receptor signaling,Chondroitin sulfate/dermatan sulfate degradation,Chondroitin sulfate biosynthesis,Heparan sulfate/heparin glycosaminoglycan (HS-GAG) metabolism |
Experiment | Prostate cancer Vs Benign Prostatic Hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | 20 patients were chosen for the study. 10 patients with Prostate Cancer and 10 patients with benign prostatic hyperplasia (BPH). |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p≤0.01 |
Method Used | Isobaric tag for relative and absolute quantitation (iTRAQ) , two-dimensional liquid chromatography-tandem mass spectrometry (2DLC-MS/MS) |
Clinical | No |
Remarks | Mean ratio corresponds to the protein reporter ion intensity originating from PCa relative to BPH. Immunohistochemistry was performed on selected genes- PSMA, AMACR, and MUC18 to confirm iTRAQ results |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | VCAN |